INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 420m ago
HOUSE PTR19m ago
SEC 13F19m ago
ROBINHOOD CHAIN19m ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Kelly John Alexander sold DTIL

Chief Financial Officer · PRECISION BIOSCIENCES INC · Common Stock

Side
SELL
Value
$61K
Shares
15.2K
Price
$4.03
Executed
Jan 21, 2026
Disclosed
Jan 22, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Jan 21 executedJan 22, 2026 disclosed

DTIL · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
27/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+8 / 25

    $61K reported value · 12.5% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+15 / 15

    3 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · DTIL

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    29
    FS
    Frankel StanleyDirector
    DTILPRECISION BIOSCIENCES INC
    Open-market purchase
    		BUY$6,000
    1,000 sh
    		Sep 28, 2026Sep 30, 2026
    traded Sep 28, 2026
    		+2dSEC FORM 4

    Evidence

    0
    SD
    Scimeca DarioGeneral Counsel and Secretary
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    14.9K sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    0
    AM
    Amoroso MichaelDirector, President and CEO
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    37.1K sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    3
    KA
    Kelly John AlexanderChief Financial Officer
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    3,888 sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    3
    KA
    Kelly John AlexanderChief Financial Officer
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    13.9K sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    0
    SJ
    Smith J. JeffersonChief Research Officer
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    2,500 sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    3
    SJ
    Smith J. JeffersonChief Research Officer
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    10.4K sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    3
    SJ
    Smith J. JeffersonChief Research Officer
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    16.2K sh
    		Jan 21, 2026Jan 22, 2026
    traded Jan 21, 2026
    		+1dSEC FORM 4

    Evidence

    24
    SJ
    Smith J. JeffersonChief Research Officer
    DTILPRECISION BIOSCIENCES INC
    Open-market sale · 10b5-1 plan
    		SELL$41K
    10.2K sh
    		Jan 21, 2026Jan 22, 2026
    traded Jan 21, 2026
    		+1dSEC FORM 4

    Evidence

    3
    AM
    Amoroso MichaelDirector, President and CEO
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    8,888 sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    7
    AM
    Amoroso MichaelDirector, President and CEO
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    37.1K sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    7
    AM
    Amoroso MichaelDirector, President and CEO
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    69.4K sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    27
    AM
    Amoroso MichaelDirector, President and CEO
    DTILPRECISION BIOSCIENCES INC
    Open-market sale · 10b5-1 plan
    		SELL$145K
    34.8K sh
    		Jan 22, 2026Jan 22, 2026
    traded Jan 22, 2026
    		+0dSEC FORM 4

    Evidence

    0
    AM
    Amoroso MichaelDirector, President and CEO
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    8,888 sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    0
    AM
    Amoroso MichaelDirector, President and CEO
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    69.4K sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    3
    SD
    Scimeca DarioGeneral Counsel and Secretary
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    1,978 sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    7
    SD
    Scimeca DarioGeneral Counsel and Secretary
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    8,425 sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    7
    SD
    Scimeca DarioGeneral Counsel and Secretary
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    14.9K sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    24
    SD
    Scimeca DarioGeneral Counsel and Secretary
    DTILPRECISION BIOSCIENCES INC
    Open-market sale · 10b5-1 plan
    		SELL$36K
    8,854 sh
    		Jan 21, 2026Jan 22, 2026
    traded Jan 21, 2026
    		+1dSEC FORM 4

    Evidence

    0
    SD
    Scimeca DarioGeneral Counsel and Secretary
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    1,978 sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001628280-26-003147
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 21, 2026
    Published
    Jan 22, 2026
    Ingested by INSIDER
    Nov 5, 04:21 UTC
    Last re-read
    Nov 5, 04:21 UTC

    Extracted facts

    Filer
    Kelly John Alexander
    Role
    Chief Financial Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    PRECISION BIOSCIENCES INC
    Ticker
    DTIL
    Shares
    15.2K
    Price per share
    $4.03
    Value
    $61,308
    Execution date (reported)
    Jan 21, 2026
    Owned after transaction
    106.4K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 15.2K
    • Price: $4.03

    = $61,308

    What this establishes

    Kelly John Alexander filed this Form 4 reporting a open-market sale of DTIL on Jan 21, 2026. It became public on Jan 22, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    Kelly John Alexandercik:0001590030
    Issuer
    PRECISION BIOSCIENCES INCcik:0001357874

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.